Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma

BACKGROUND: RECORD-3 assessed non-inferiority of progression-free survival (PFS) with everolimus vs sunitinib in previously untreated patients with metastatic renal cell carcinoma. Baseline plasma sample collection and randomised design enabled correlation of circulating biomarkers with efficacy. ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Voss, Martin H, Chen, David, Marker, Mahtab, Hakimi, A Ari, Lee, Chung-Han, Hsieh, James J, Knox, Jennifer J, Voi, Maurizio, Motzer, Robert J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800293/
https://ncbi.nlm.nih.gov/pubmed/26908330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.21
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados